REG - Arecor Therapeutics - Result of AGM

Arecor TherapeuticsAnnouncement

02/06/2025 13:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250602:nRSB0564La&default-theme=true

RNS Number : 0564L  Arecor Therapeutics PLC  02 June 2025

Arecor Therapeutics plc

 

("Arecor", the "Company" or the "Group")

 

RESULT OF AGM

 

Cambridge, UK, 2 June 2024: Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical company advancing today's therapies to enable healthier
lives, announces that at its Annual General Meeting, held today at 09.30 am,
all eleven resolutions put to members were passed. Resolution 8 was made
redundant and bypassed.

 

The full text of each resolution was included in the Company's Notice of
Annual General Meeting made available on the Company's website
(https://arecor.com/investor-centre/shareholder-information/) .

 

The number of proxy votes cast for and against each of the resolutions
proposed, and the number of proxy votes withheld were as follows:

 

 Resolution                                                                      Votes for   %      Votes against  %     Votes withheld
 Resolution 1                                                                    17,521,432  100    0              0     174,884

 To receive the directors' report, the consolidated financial statements and
 the auditors' report for the year ended 31 December 2024
 Resolution 2                                                                    15,574,064  91.31  1,481,955      8.69  640,297

 To approve the directors' remuneration report as set out on pages 36 to 38 in
 the annual report for the year ended 31 December 2024
 Resolution 3                                                                    17,547,867  100    0              0     148,449

 To re-elect Sarah Howell as a Director of the Company in accordance with the
 articles
 Resolution 4                                                                    16,586,103  94.52  961,764        5.48  148,449

 To re-elect Andrew Richards as a Director of the company in accordance with
 the articles
 Resolution 5                                                                    15,881,200  90.50  1,666,667      9.50  148,449

 To re-elect Sam Fazeli as a Director of the Company in accordance with the
 articles
 Resolution 6                                                                    17,547,867  100    0              0     148,449

 To re-elect Jeremy Morgan as a Director of the Company in accordance with the
 articles
 Resolution 7                                                                    17,547,867  100    0              0     148,449

 To re-elect Christine Soden as a Director of the Company in accordance with
 the articles
 Resolution 8

 To re-elect Alan Smith as a Director of the Company is redundant and was
 bypassed.
 Resolution 9                                                                    17,525,016  99.88  21,620         0.12  149,680

 To re-appoint Grant Thornton as auditors of the Company
 Resolution 10                                                                   17,537,747  99.94  10,120         0.06  148,449

 To authorise the Directors to agree the auditors' remuneration
 Resolution 11                                                                   16,580,991  99.60  67,376         0.40  1,047,949

 To authorise the allotment of shares
 Resolution 12 (special)                                                         16,580,842  99.93  11,500         0.07  1,103,974

 To disapply statutory pre-emption rights

 

-ENDS-

 

For more information, please contact:

 

 Arecor Therapeutics plc                                 www.arecor.com
 Dr Sarah Howell, Chief Executive Officer                Tel: +44 (0) 1223 426060

                                                         Email: info@arecor.com (mailto:info@arecor.com)
 David Ellam, Chief Financial Officer                    Tel: +44 (0) 1223 426060

                                                         Email: info@arecor.com (mailto:info@arecor.com)

 Singer Capital Markets Advisory LLP (NOMAD and Broker)
 Phil Davies, Sam Butcher                                Tel: +44 (0) 20 7496 3000

 ICR Healthcare
 Chris Gardner, David Daley, Lindsey Neville             Tel: +44 (0) 20 3709 5700

                                                         Email: arecor@icrhealthcare.com (mailto:arecor@icrhealthcare.com)

 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary technology platform, Arestat™, we are developing an internal
portfolio of proprietary products in diabetes and other indications, as well
as working with leading pharmaceutical and biotechnology companies to deliver
therapeutic products. The Arestat™ platform is supported by an extensive
patent portfolio.  For further details please see our website, www.arecor.com
(http://www.arecor.com)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGPKBBBBBKDPAK